Faricimab
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Faricimab: From Retinal Vascular Disease to Primary Release Disorder of Platelets
One-Sentence Summary
Faricimab is an intravitreal bispecific antibody registered in Singapore and used for retinal vascular disease. The TxGNN model predicts it may be effective for primary release disorder of platelets, a rare inherited bleeding disorder. Currently 0 clinical trials and 0 publications support this prediction, so it rests on the model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore registration record. Faricimab is an intravitreal agent for retinal vascular diseases. |
| Predicted New Indication | Primary release disorder of platelets |
| TxGNN Prediction Score | 98.89% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Faricimab is a bispecific antibody that neutralises two targets, VEGF-A and angiopoietin-2 (Ang-2). Together they drive vascular leakage, inflammation, and abnormal blood vessel growth in the eye. It is given by injection into the eye and has minimal systemic exposure. Detailed mechanism-of-action data were not available in the data compiled for this report, so this description comes from the mechanistic assessment of the predicted indication.
On the available information, this prediction is not mechanistically plausible:
- A platelet granule release defect is not driven by VEGF-A or Ang-2 signalling, so faricimab has no pathway overlap with the disease.
- The high TxGNN score reflects a pattern in a knowledge graph, not clinical or laboratory evidence.
- No clinical trial or publication links faricimab to this condition.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16514P | VABYSMO SOLUTION FOR INJECTION 6MG/0.05ML | Injection, solution | Not stated in the registration record |
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no clinical, literature, or mechanistic support (L5). Faricimab's targets are unrelated to platelet granule release, and the drug is formulated and dosed for intravitreal use, not for a systemic bleeding disorder.
To proceed, the following is needed:
- A credible biological rationale linking VEGF-A or Ang-2 blockade to platelet release function
- Preclinical or laboratory data in relevant platelet models
- The Singapore package insert warnings and contraindications, which were not available for this review
- Detailed mechanism-of-action data from DrugBank
Note on other predictions: In the same prediction list, diabetic retinopathy (rank 8, TxGNN score 96.75%) has much stronger support. It has L1 evidence, including Phase 3 trials in diabetic macular edema (YOSEMITE/RHINE), a completed Phase 2 trial in non-proliferative disease (MAGIC, NCT05681884), and a recruiting Phase 3 trial in proliferative disease (NCT06790784). If you are looking for a repurposing direction for faricimab, that indication is the better candidate for a separate evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.